Clinical Trial: Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional



Official Title: Phase 2 Study of Everolimus Therapy in Patients With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer

Brief Summary:

Background:

- Research has shown that the drug everolimus can stop cancer cells from growing. It is approved for people with advanced kidney cancer. Researchers want to see if it also helps people with two other types of kidney cancer.

Objective:

- To see if everolimus is safe and effective in people with Birt-Hogg-Dube Syndrome (BHD)-associated kidney cancer or sporadic (nonfamilial) chromophobe renal cancer.

Eligibility:

- People ages 18 and over with BHD-associated kidney cancer or advanced sporadic chromophobe renal cancer.

Design:

  • Participants will be screened with:
  • Medical history, physical exam, and blood and urine tests.
  • Computed tomography (CT) scan or magnetic resonance imaging (MRI) scan. They will lie in a machine that takes pictures of their chest/abdomen/pelvis.
  • They may also be screened with:
  • Another scan, of the brain or neck.
  • Bone scan.
  • Positron emission tomography scan with fludeoxyglucose (FDG-PET).
  • Heart and lung tests.
  • Tests for hepatitis.
  • Participants will take a tablet once a day by mouth for up to a year. They will keep a diary of when they take the tablet and any symptoms.
  • During the study, participants will have physical exams and urine and blood tests. They will have scans of